SCHEMBL26109399

SCHEMBL26109399

OCc1cc(Cl)nc2c1ccn2Cc1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HRH4 Q9H3N8 1/20 0.42
▸ MAOB P27338 3/20 0.42
▸ HTR6 P50406 2/20 0.42
▸ FLT1 P17948 1/20 0.41
▸ KDR P35968 1/20 0.41
▸ HRH3 Q9Y5N1 2/20 0.41
▸ DHPS P49366 1/20 0.41
▸ NOTUM Q6P988 1/20 0.41
▸ HDAC1 Q13547 2/20 0.40
▸ HDAC2 Q92769 1/20 0.40
▸ ABL1 P00519 1/20 0.39
▸ FYN P06241 1/20 0.39
▸ SRC P12931 1/20 0.39
▸ FLT3 P36888 1/20 0.39
▸ EGLN1 Q9GZT9 3/20 0.39
▸ VEGFA P15692 1/20 0.38
▸ POLB P06746 2/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ LMNA P02545 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26108715 0.83 MCL1 (0.35) MAOBHTR6HDAC1HDAC2POLB
SCHEMBL31347139 0.81 KMT2A (0.33) MAOBHTR6HDAC1KDM4EALDH1A1
SCHEMBL26104758 0.81 KMT2A (0.33) MAOBHTR6HDAC1KDM4EALDH1A1
SCHEMBL26107594 0.79 SRC (0.35) ABL1SRCEGLN1POLBKDM4E
SCHEMBL31347134 0.79 SRC (0.35) ABL1SRCEGLN1POLBKDM4E
SCHEMBL31347050 0.78 TLR7 (0.39) HDAC1FYNSRCFLT3POLB
SCHEMBL30611967 0.78 LMNA (0.34) ALDH1A1LMNA
SCHEMBL26106118 0.78 LMNA (0.34) ALDH1A1LMNA
SCHEMBL26105348 0.78 TLR7 (0.39) HDAC1FYNSRCFLT3POLB
SCHEMBL26105101 0.77 HRH4 (0.41) HRH4FLT1KDRHRH3NOTUM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250214991-A1 BICYCLIC HETEROARYL-CONTAINING COMPOUNDS AS IKZF2 DEGRADERS ONCOPIA THERAPEUTICS, INC. D/B/A/ SK LIFE SCIENCE LABS 2025-07-03 — — US disclosed
CN-119585252-A Bicyclic heteroaryl containing compounds as IKZF2 degrading agents 翁科皮亚治疗公司和SK生命科学实验室 2025-03-07 — — CN disclosed
EP-4499629-A1 BICYCLIC HETEROARYL-CONTAINING COMPOUNDS AS IKZF2 DEGRADERS Oncopia Therapeutics, Inc. D/B/A SK Life Science Labs (US) 2025-02-05 — — EP disclosed
WO-2023183919-A1 BICYCLIC HETEROARYL-CONTAINING COMPOUNDS AS IKZF2 DEGRADERS ONCOPIA THERAPEUTICS, INC. D/B/A PROTEOVANT THERAPEUTICS, INC. (US) 2023-09-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250214991-A1 BICYCLIC HETEROARYL-CONTAINING COMPOUNDS AS IKZF2 DEGRADERS IKZF1, IKZF2, IKZF3 HRH4 4461/4885MAOB 3165/4885HTR6 3903/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback